Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Contezolid - MicuRx Pharmaceuticals

Next Previous
Drug Profile

Contezolid - MicuRx Pharmaceuticals

Alternative Names: MRX I; Youxitai

Latest Information Update: 16 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MicuRx Pharmaceuticals
  • Class Amines; Anti-infectives; Antibacterials; Antituberculars; Dihydropyridines; Fluorinated hydrocarbons; Foot disorder therapies; Oxazoles; Oxazolidinones; Skin disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Diabetic foot
  • No development reported Tuberculosis

Most Recent Events

  • 01 Nov 2024 Phase-III clinical trials in Diabetic foot (Combination therapy, In the elderly, In adults) in Argentina, Brazil, Bulgaria, Chile, China, Croatia, Estonia, Georgia, Latvia, Slovakia, Serbia, Spain (PO), prior to November 2024 (NCT05369052)
  • 22 Sep 2023 Contezolid receives Fast Track designation for Diabetic foot [PO, Tablet] (Combination therapy, In the elderly, In adults) in USA
  • 22 Sep 2023 Contezolid receives Qualified Infectious Disease Product status for Diabetic foot in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top